KALA

Kala Bio Inc

0.1936

Oct 21 • 10:51 AM ET +0.0039 (2.06%)

Healthcare Biotechnology USA Nano NASD

Peers: LNAI KPRX KLRS BFRG OKYO CDIO SKYE ENVB MGRX LFMD

Index	-
Market Cap	3.75M
Enterprise Value	-3.48M
Income	-10.08M
Sales	0.00M
Book/sh	0.47
Cash/sh	0.37
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6
IPO	Jul 20, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.41
P/C	0.52
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.88
Current Ratio	6.88
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-73.93
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	51.75% 49.38%
Sales past 3/5Y	- -
EPS Y/Y TTM	78.25%
Sales Y/Y TTM	-
EPS Q/Q	75.10%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	-0.39% -

Insider Own	3.89%
Insider Trans	0.00%
Inst Own	3.63%
Inst Trans	3.58%
ROA	-43.23%
ROE	-345.32%
ROIC	-111.46%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-41.21%
SMA50	-64.23%
SMA200	-97.55%
Trades

Shs Outstand	19.34M
Shs Float	18.59M
Short Float	7.31%
Short Ratio	0.92
Short Interest	1.36M
52W High	95.50 -99.80%
52W Low	0.11 68.94%
Volatility	36.67% 19.59%
ATR (14)	0.05
RSI (14)	21.69
Beta	-2.31
Rel Volume	0.28
Avg Volume	1.48M
Volume	105,040

Perf Week	2.98%
Perf Month	-67.68%
Perf Quarter	-68.28%
Perf Half Y	-97.81%
Perf YTD	-99.30%
Perf Year	-99.58%
Perf 3Y	-99.95%
Perf 5Y	-100.00%
Perf 10Y	-
Recom	3.00
Target Price	1250.00
Prev Close	0.19
Price	0.19
Change %	2.06%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-25	Downgrade	Mizuho	Outperform → Neutral	$1.50
Sep-29-25	Downgrade	Ladenburg Thalmann	Buy → Neutral
Sep-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-08-25	Initiated	Mizuho	Outperform	$30
Jul-11-25	Initiated	Ladenburg Thalmann	Buy	$12
Mar-30-22	Downgrade	JP Morgan	Neutral → Underweight
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Sep-14-20	Downgrade	Jefferies	Buy → Hold	$10
Jul-23-20	Initiated	Northland Capital	Outperform
Jun-01-20	Resumed	Oppenheimer	Outperform	$21
May-27-20	Reiterated	H.C. Wainwright	Buy	$14 → $17
Mar-09-20	Upgrade	BofA/Merrill	Neutral → Buy
Dec-17-19	Downgrade	BofA/Merrill	Buy → Neutral	$9 → $6
Mar-14-19	Initiated	Jefferies	Buy	$15

Show Previous Ratings

Sep-29-26 07:30AM	KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception (Newsfile) +11.79%
Sep-24-26 07:30AM	Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products (GlobeNewswire)
Sep-17-26 07:30AM	KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team (GlobeNewswire) +8.24%
Sep-03-26 09:47AM	Kala Bio Signs Exclusive U.S. Distribution Agreement for Virotek Ophthalmology Genetic Tests (InvestorsHub) +7.37%
08:30AM	Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program (GlobeNewswire)
11:05AM	Loading…
Sep-01-26 11:05AM	Kala Bio Targets Near-Term Revenue With Virotek Ophthalmology Genetic Testing Partnership (InvestorsHub) -20.89%
07:45AM	Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program (GlobeNewswire)
Aug-19-26 04:32PM	KALA BIO: Q2 Earnings Snapshot (Associated Press) -6.66%
May-15-26 03:36PM	KALA BIO: Q1 Earnings Snapshot (Associated Press) -5.18%
May-07-26 09:00AM	KALA BIO Announces Reverse Stock Split (GlobeNewswire) -27.80%
Apr-21-26 07:00AM	Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine (GlobeNewswire) -7.45%
Apr-15-26 04:14PM	KALA BIO: Q4 Earnings Snapshot (Associated Press) -11.96%
Apr-01-26 06:45AM	Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities (GlobeNewswire) -5.83%
Mar-30-26 08:45AM	KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live (GlobeNewswire)
Mar-18-26 09:00AM	Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate (GlobeNewswire)
08:15AM	Loading…
08:15AM	Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate (Newsfile)
Mar-11-26 11:18AM	Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New 'AutoResearch' Milestone Signals the Rise of Autonomous Research Agents (Newsfile) +24.16%
06:30AM	Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates (GlobeNewswire)
Mar-09-26 06:20AM	Stock Trend Capital Provides Younet AI Investment Update (TMX Newsfile) -6.33%
Mar-04-26 01:05PM	KALA BIO Eyes Pharma R&D Spend With Secure AI Licensing Model (Benzinga)
06:30AM	KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform "Researgency" (GlobeNewswire)
Jan-05-26 04:10PM	KALA BIO Settles Approximately $10.6 million of Debt (GlobeNewswire) +6.90%
Dec-05-25 02:36PM	KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -6.64%
Dec-04-25 10:45AM	KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Dec-01-25 07:00AM	KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar (GlobeNewswire) +37.67%
Nov-19-25 06:11PM	KALA BIO: Q3 Earnings Snapshot (Associated Press Finance) -8.10%
Oct-08-25 11:18AM	KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure (Zacks)
Sep-29-25 08:00AM	KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint (GlobeNewswire) -89.27%
Sep-03-25 08:00AM	KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +23.13%
Sep-02-25 08:00AM	KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director (GlobeNewswire) +8.65%
09:55AM	Loading…
Aug-13-25 09:55AM	Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade (Zacks) +5.78%
Aug-08-25 08:08AM	KALA BIO: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-06-25 08:00AM	KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Jul-28-25 08:23AM	Zacks.com featured highlights include KALA, Graham, Arq and Hawkins (Zacks)
Jul-25-25 11:55AM	Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility (Zacks) +15.57%
Jul-09-25 08:00AM	KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) (GlobeNewswire) +22.09%
Jul-07-25 08:00AM	KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) (GlobeNewswire)
May-29-25 08:00AM	KALA BIO to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-25 08:00AM	KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -6.03%
Mar-31-25 08:00AM	KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.29%
Feb-26-25 08:00AM	KALA BIO to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-12-25 08:00AM	KALA BIO Announces Chief Executive Officer Transition (GlobeNewswire) -31.62%
Dec-30-24 08:00AM	KALA BIO Announces $10,750,000 Private Placement (GlobeNewswire)
Nov-27-24 08:00AM	KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-12-24 08:00AM	KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-24 08:00AM	KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) -6.35%
Aug-06-24 01:53PM	KALA Stock Earnings: Kala Bio Beats EPS for Q2 2024 (InvestorPlace)
08:00AM	KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-27-24 08:00AM	KALA BIO Announces $12,500,000 Private Placement (GlobeNewswire) +40.22%
May-29-24 08:00AM	KALA BIO to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-24 01:13PM	Wall Street Analysts Just Trimmed Price Target for KALA BIO, Inc. (NASDAQ:KALA) (Insider Monkey)
11:17AM	Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks (Insider Monkey)
May-14-24 10:54PM	KALA Stock Earnings: Kala Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-02-24 07:53AM	KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
Mar-29-24 08:00AM	KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-26-24 08:00AM	KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference (GlobeNewswire)
Feb-06-24 08:00AM	KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-19-24 04:01PM	KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.91%
Nov-13-23 08:00AM	KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-20-23 04:01PM	KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-23 08:00AM	KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -11.58%
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-04-23 08:11AM	Kala Pharma: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-02-23 04:01PM	KALA BIO to Participate in Upcoming Investor Conferences in August (GlobeNewswire) -5.28%
08:00AM	Kala Pharmaceuticals Announces Name Change to KALA BIO (GlobeNewswire)
Jul-19-23 04:01PM	Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-23-23 04:01PM	Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-23 08:00AM	Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire) +11.17%
May-11-23 12:20PM	10 Best Stocks to Buy for a Quick Return (Insider Monkey) +15.57%
May-09-23 08:07AM	Kala Pharma: Q1 Earnings Snapshot (AP Finance)
08:00AM	Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-28-23 08:00AM	Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED (GlobeNewswire)
Apr-14-23 12:49PM	Regulus (RGLS) Surges on Enrollment Completion for RGLS8429 (Zacks) -6.78%
Apr-13-23 11:22AM	Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News (Zacks)
11:10AM	KALA Up on Fast Track Designation to Lead Ocular Candidate (Zacks)
Apr-12-23 08:00AM	Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect (GlobeNewswire)
Apr-05-23 05:50PM	Kala Pharmaceuticals (KALA) Dips More Than Broader Markets: What You Should Know (Zacks)
Apr-04-23 01:32PM	CRISPR (CRSP) & Vertex Complete BLA Submission for Exa-Cel (Zacks)
01:16PM	Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study (Zacks)
Mar-30-23 05:50PM	Kala Pharmaceuticals (KALA) Stock Sinks As Market Gains: What You Should Know (Zacks)
Mar-29-23 08:00AM	Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor (GlobeNewswire) -5.73%
Mar-28-23 11:04AM	Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe (Zacks)
Mar-27-23 08:00AM	Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED (GlobeNewswire)
Mar-24-23 09:55AM	Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know (Zacks) +6.43%
Mar-23-23 11:09AM	Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders (Zacks)
Mar-22-23 09:30AM	Kala Pharmaceuticals (KALA) Recently Broke Out Above the 200-Day Moving Average (Zacks) -6.47%
07:37AM	Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals (Zacks)
Mar-20-23 12:04PM	Axsome (AXSM) Stock Up 17% in Six Months: Here's Why (Zacks) -8.95%
09:30AM	Wall Street Bulls Look Optimistic About Kala Pharma (KALA): Should You Buy? (Zacks)
Mar-17-23 02:54PM	Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001 (Zacks)
Mar-09-23 09:30AM	Kala Pharmaceuticals (KALA) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks) -13.76%
Mar-08-23 04:01PM	Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire) +15.95%
09:55AM	How Much Upside is Left in Kala Pharma (KALA)? Wall Street Analysts Think 143.91% (Zacks)
Mar-06-23 12:33PM	KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus (Zacks) +33.37%
Mar-03-23 03:02PM	Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating (Investor's Business Daily) +64.70%
08:00AM	Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-02-23 09:30AM	Wall Street Analysts Think Kala Pharma (KALA) Is a Good Investment: Is It? (Zacks) +6.72%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ANDREW I KOVEN	Director	Mar 17 '26	Proposed Sale	0.26	14,466	3,816		Mar 17 04:21 PM
Howard B Rosen	Director	Mar 12 '26	Proposed Sale	0.29	13,576	3,975		Mar 12 05:40 PM
CHARLES D MYERS	Director	Mar 12 '26	Proposed Sale	0.31	9,112	2,858		Mar 12 04:04 PM
Iwicki Mark T	Director	Oct 23 '25	Sale	0.81	154,894	125,464	103,540	Oct 24 08:00 PM
Reumuth Mary	CHIEF FINANCIAL OFFICER	Oct 22 '25	Sale	0.83	32,230	26,751	29,873	Oct 24 08:00 PM
Reumuth Mary	CHIEF FINANCIAL OFFICER	Oct 23 '25	Sale	0.82	967	793	28,906	Oct 24 08:00 PM
Bazemore Todd	Director	Oct 22 '25	Sale	0.83	47,768	39,647	35,932	Oct 24 08:00 PM
Brazzell Romulus K	SEE REMARKS	Oct 22 '25	Sale	0.83	46,748	38,801	35,952	Oct 24 08:00 PM
Kharabi Darius	CHIEF BUSINESS OFFICER	Oct 22 '25	Sale	0.83	20,806	17,269	41,760	Oct 24 08:00 PM
MARK IWICKI	Director	Oct 23 '25	Proposed Sale	0.81	154,894	125,185		Oct 23 07:03 PM
MARY REUMUTH	Officer	Oct 23 '25	Proposed Sale	0.82	967	793		Oct 23 04:02 PM
MARY REUMUTH	Officer	Oct 22 '25	Proposed Sale	0.83	32,230	26,728		Oct 22 07:07 PM
R K BRAZZELL	Officer	Oct 22 '25	Proposed Sale	0.83	46,748	38,964		Oct 22 06:21 PM
TODD M BAZEMORE	Officer	Oct 22 '25	Proposed Sale	0.83	47,768	39,686		Oct 22 06:08 PM
DARIUS KHARABI	Officer	Oct 22 '25	Proposed Sale	0.83	20,806	17,284		Oct 22 05:10 PM

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Treasurer & SecretaryMs. Mary Reumuth CPA

CEOMr. Avi Minkowitz

Founder & Chair of the Scientific Advisory BoardDr. Justin Hanes Ph.D.

Executive Director of Investor Relations & Corporate CommunicationsMs. Jill S. Steier

Senior VP of Manufacturing & Supply Chain ManagementMr. Vincent Kosewski

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KALA

Kala Bio Inc

Upgrade your Finviz experience